Type 2 Diabetes and Blood Brain Barrier Improvement
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Mar 13, 2024
Trial Information
Current as of August 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a vitamin called thiamine (or vitamin B1) might help improve brain function in adults with Type 2 diabetes. Many people with this condition have low levels of thiamine, which could affect how their brains work. The researchers will use brain scans, tests to check thinking skills, blood tests, and questionnaires to see if taking thiamine capsules can make a difference. Participants will need to visit UCLA two times, three months apart, with each visit lasting about 2.5 to 3 hours.
To join the study, participants must be diagnosed with Type 2 diabetes and able to lie flat for the brain scans. However, people with certain conditions, such as a history of stroke, current thiamine use, or significant breathing issues, cannot participate. It’s important for potential participants to know that they will undergo some testing to determine if they are eligible and to ensure their safety during the trial. If interested, this could be a great opportunity to contribute to research that may help improve brain health for those living with Type 2 diabetes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed T2DM
- • Outpatient status
- • Able to lay flat for imaging
- Exclusion Criteria:
- • A previous history of stroke
- • Current in-take of thiamine
- • Known thiamine allergy
- • Seizure disorder
- • Head trauma
- • Myocardial infarction
- • Current pregnancy (if female)
- • Diagnosed neuropsychiatric disorders (clinical depression, schizophrenia, manic-depression)
- • Diagnosed dementia
- • Sleep disordered breathing
- • Airway or chest deformities that would interfere with breathing
- • Chronic obstructive pulmonary disease
- • Cystic fibrosis
- • Presence of brain mass lesions
- • Any history of drug abuse (e.g., cocaine, tobacco, or cannabis)
- • Renal failure (requiring dialysis)
- • All T2DM adults with metallic and electronic implants (phrenic or cardiac pacemakers; although some pacemakers and cardioverter defibrillators are safe at a low magnetic field, they are not safe at 3.0-Tesla scanner)
- • Non-removable insulin pump/glucose sensor
- • Braces
- • Body weight more than 300 pounds (weight and height will be used to calculate BMI to determine if the patient will fit in the scanner and stay within parameters of size restrictions of MRI scanner table)
- • Any other contraindications to MRI, such as claustrophobia, or metallic-based tattoos, as per MRI safety website suggestions, will also be excluded.
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported